| Company Name: | Hansen Medical, Incorporated | | Ticker Symbol: | HNSN | | | WWW Address: | www.hansenmedical.com | | CEO: | Dr. Frederic H. Moll, M.D., Ph.D. | | No. of Employees: | 208 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures and markets a new generation of medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.65 |  -0.11 | 2.5 | 3.02 | 2.76 | 2.76 | 2.62 | 189620 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 99.2 | 37.4 | 1.63 | -2.21 | 0.00 | 0.0 | 0.0 | 9.57 - 2.50 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.65 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 99.2 | mil |
| Latest Shares Outstanding | 37.4 | mil |
| Earnings pS (EPS) | -2.21 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 145,351 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 35.3 | mil |
| Float as % of Shares Outstanding | 94.4 | % |
| Foreign Sales | 10 | mil |
| Domestic Sales | 20 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 171.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 100.00 | % |
| Gross Profit Margin | 45.1 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -75.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -109.0 | % |
| Current Ratio | 2.8 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.24 | |
| LT Debt/Total Capital | 14.0 | % |
| Working Capital pS | 1.01 | $ |
| Cash pS | 0.32 | $ |
| Book-Value pS | 1.18 | $ |
| Tangible Book-Value pS | 1.18 | $ |
| Cash Flow pS | -1.37 | $ |
| Free Cash Flow pS | -1.05 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.25 | |
| Price/Tangible Book Ratio | 2.25 | |
| Price/Cash Flow | -1.9 | |
| Price/Free Cash Flow | -2.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.9 | 97 | 4,425 | 4,321 |
| 4 Weeks | 3.29 | 2.50 | 2.56 | 3.5 | 97 | 3,460 | 58,822 |
| 13 Weeks | 4.58 | 2.50 | 3.34 | -20.7 | 74 | 4,903 | 299,087 |
| 26 Weeks | 5.85 | 2.50 | 5.69 | -53.4 | 39 | 4,784 | 597,956 |
| 52 Weeks | 9.57 | 2.50 | 9.19 | -71.2 | 23 | 3,619 | 901,047 |
| YTD | 8.52 | 2.50 | - | -63.3 | 30 | 3,820 | 867,100 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.70 | 2.83 | 3.15 | 3.95 | 3.95 | 1.63 | 1.63 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 245.51 |
| R&D | 0.00 | NA | 12.13 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -34.7 | -58.0 | 199.8 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.36 | 0.16 | 0.12 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 56.30 |
| Current Ratio | 4.1 |
| Quick Ratio (Acid Test) | 3.4 |
| Liquidity Ratio (Cash) | 2.71 |
| Receivables Turnover | 4.5 |
| Average Collection Period | 80 |
| Working Capital/Equity | 85.0 |
| Working Capital pS | 1.60 |
| Cash-Flow pS | -2.00 |
| Free Cash-Flow pS | -2.51 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.06 |
| Financial Leverage Ratio (Assets/Equity) | 1.5 |
| Debt Ratio | 33.8 |
| Total Debt/Equity (Gearing Ratio) | 0.26 |
| LT Debt/Equity | 0.21 |
| LT Debt/Capital Invested | 19.6 |
| LT Debt/Total Liabilities | 41.2 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 1.07 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.80 |
| Tobin's Q Ratio | 1.38 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.73 |
| Enterprise Value (EV)/Free Cash Flow | -1.49 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.25 |
| Price/Book Ratio - LTM | 2.25 |
| Price/Cash Flow Ratio | -1.9 |
| Price/Free Cash Flow Ratio - LTM | -2.5 |
| Price/Sales Ratio | 4.45 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.40 |
| Current Liabilities pS | 0.51 |
| Tangible Book Value pS - LTM | 1.18 |
| Book Value pS - LTM | 1.18 |
| Capital Invested pS | 1.54 |
| Cash pS - LTM | 0.32 |
| Cash Flow pS - LTM | -1.37 |
| Free Cash Flow pS - LTM | -1.05 |
| Earnings pS (EPS) | -2.21 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -209.60 |
| Free Cash Flow Margin 5YEAR AVG | -122.16 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.63 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.52 |
| Return on Capital Invested (ROCI) | -92.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -100.8 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -74.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | -56.7 |
| Gross Profit Margin | 45.1 |
| Gross Profit Margin - 5YEAR AVRG. | 39.1 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 206 |
| Revenue per Employee | 145,351 |
| Net Income per Employee | -256,942 |
| Average Collection Period | 113 |
| Receivables Turnover | 4.5 |
| Day's Inventory Turnover Ratio | 93 |
| Inventory Turnover | 3.9 |
| Inventory/Sales | 22.1 |
| Accounts Payble/Sales | 10.19 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 0.75 |
| Fixed Assets Turnover | 1.64 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 1.74 |
| Revenue per $ Plant | 1.66 |
| Revenue per $ Common Equity | 0.63 |
| Revenue per $ Capital Invested | 0.52 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 122.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 193.2 |
| Research & Devlopment (R&D) as % of Revenue | 84.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 84.6 |
|
|  
|
| |
 |  |